Topic:

M&A

Latest Headlines

Latest Headlines

BioMarin shares climb on Shire takeover buzz

The M&A rumor mill was churning Friday morning on reports of an in-the-works Shire ($SHPG) deal for orphan drugmaker BioMarin Pharmaceuticals.

Shire, BioMarin and the snowball effect of buyout rumors

Shire is an acquisitive company with a focus on rare diseases. BioMarin fits the same description. A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts combined to send the shares of BioMarin, far from a penny stock, up as much as 15% on Friday, illustrating how the biotech boom has changed Wall Street's perception of the drug industry.

Medtronic slides into hearing devices with magnetic implant startup acquisition

Hearing devices have not been among Medtronic's competencies--until now. The medical device giant has bought magnetic hearing implant startup Sophono for an undisclosed amount. Sophono's implant is the smallest and most effective at higher frequencies, according to the startup and Medtronic.

After Salix's $10B deal, is Synergy Pharma on the block?

Gastro drug developer Synergy Pharmaceuticals is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals.

What does Merck's $10B buyback plan say about pharma M&A?

Adding $10 billion to its stock buyback program might mean Merck & Co. wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But  The Wall Street Journal  sees a different possibility--one the rest of the industry might want to pay attention to.

Amoun Pharma investors make another run at a $700M-plus sale

It's try, try again for Egypt-based Amoun Pharmaceuticals. The drugmaker, among the largest in its home country, hired Goldman Sachs to look for potential buyers after previous efforts failed.

Legal fallout from Valeant's failed Allergan siege? Experts debate

Now that Actavis' $66 billion Allergan buy--and the bitter takeover war between Allergan and Valeant that preceded it--are in the books, there's much to reflect on. And a lot of lingering questions about how the saga will impact dealmaking moving forward, too.

Becton Dickinson plans respiratory asset sale in wake of CareFusion merger

Becton Dickinson is reviewing its assets now that the $12.4 billion CareFusion deal closed last week. The $30 billion medical products and diagnostics company is expected to sell the respiratory device business that was formerly part of CareFusion, Bloomberg reports.

AbbVie's $21B buyout puts Pharmacyclics execs in line for $4B payoff

Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie's $21 billion buyout goes through. But considering Duggan's record, a multibillion-dollar payoff is to be expected. It's the other executives and directors--who together qualify for more than $575 million--who could inspire M&A envy.

VCA division Antech buys Abaxis vet-lab assets for $21M

Antech Diagnostics, the lab division of veterinary hospital chain VCA, has agreed to buy the assets of Abaxis' Veterinary Reference Laboratory for $21 million in cash.